Merck will have early-stage opportunities to help startups set up for future success in the pharmaceutical and life sciences fields.

As has been the case for several quarters now, Merck KGaA’s life science business continues to serve as a weathervane for the ...

Sanofi plans to invest $20 billion in U.S.-based drug R&D and manufacturing over five years, creating jobs and boosting ...

We believe that Merck KGaA enjoys a narrow moat, driven by intangible assets and switching costs which are prevalent in its Life Science and Electronics businesses. A few acquisitions to fill gaps in ...

Roche warned that President Trump's executive order on drug pricing threatens its planned $50 billion investment in the ...

This cash-strapped company is shifting from its roots in cancer drug development to focus on cosmetic treatments.

Germany's Merck KGaA shares plunged after the company slashed its full-year outlook on the back of uncertainty around tariffs and foreign-exchange headwinds. In European morning trading shares were ...

Press Release Top decision-makers from across the biopharma ecosystem will convene in Chicago for the 2nd BioCentury Grand Rounds – U.S., at the intersection of research, investment and drug ...

Recursion Pharmaceuticals faces a 57% stock drop amid drug setbacks, rising cash burn, and AI discovery doubts. Learn more ...

Add Sanofi to the list of drugmakers committing billions to bolster their operations in the United States as President Donald ...

Merck (NYSE:MRK) is set to showcase significant research advancements, including updates on its KEYTRUDA indications at the upcoming ASCO Annual Meeting, which could enhance its oncology footprint.

A consultancy’s new ranking of drug company R&D shows Eli Lilly has risen to the top of the drug development heap, while ...